Kateryna Kravchenko

I joined the Wade-Martins Group to contribute to ongoing projects investigating lysosomal dysfunction and its role in neurodegenerative diseases, with a particular focus on Parkinson’s disease. My work supports studies conducted in collaboration with the Oxford-based biotech company EndLyz, which explore how modulation of lysosomal pathways can influence disease mechanisms and therapeutic responses in cellular models of neurodegeneration. I obtained my B.Sc. in Cell and Molecular Biology from the University of Strasbourg, which included an exchange year at the Karolinska Institutet, where I studied the molecular details of the mtLon–DNA interaction and its implications for mitochondrial metabolism using cryo-electron microscopy. I then completed an M.Phil. at the University of Cambridge, focusing on the regulation of genome architecture by the chromatin remodelling protein CHD4 in mouse embryonic stem cells. I am broadly interested in understanding the molecular and intracellular mechanisms underlying neurodegeneration, particularly how alterations in protein homeostasis and organelle function contribute to disease progression.